drugset / Trial / NCT04767295
A Study of Camrelizumab Combined With Chemotherapy as Neoadjuvant Therapy in Adcanced Esophageal Squamous Cell Carcinoma (ESCC)
NaSingle-groupOpen-labelTreatment
Summary
To evaluate the efficacy and safety of camrelizumab combined with albumin paclitaxel and platinum chemotherapy in the preoperative treatment of locally advanced thoracic esophageal squamous cell carcinoma
Timeline
- Start
- 2021-03-01
- Primary completion
- 2023-03-01
- Completion
- 2023-03-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Camrelizumab | Monoclonal antibody | 200 mg | Intravenous |
| Subject | Carboplatin | Small molecule | 4 unknown | Intravenous |
| Subject | Paclitaxel | Small molecule | 260 mg/m2 | Intravenous |